Navigation Links
Seattle Genetics Highlights Data on its Proprietary Antibody-Drug,Conjugate Technology at AACR

BOTHELL, Wash. & LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data from fifteen presentations by the company and its collaborators at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) demonstrating preclinical advances with its proprietary antibody-drug conjugate (ADC) technology and cancer product pipeline.

ADCs are monoclonal antibodies linked to cell-killing drugs. Seattle Genetics' ADC technology employs synthetic, highly potent drugs that are bound to monoclonal antibodies through proprietary linker systems. The linkers are designed to be stable in the bloodstream but to release the drug payload under specific conditions once inside target cells, thereby sparing non-target cells many of the toxic effects of traditional chemotherapy.

"Empowered antibodies utilizing our ADC technology have the potential to significantly impact the way cancer is treated," said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. "Our strong presence at AACR this year reflects continued progress with our proprietary and partnered ADC programs. We expect to report clinical data from the ongoing phase I dose-escalation trial of SGN-35, our lead ADC, later this year, while both we and our collaborators continue to advance additional ADC programs into and towards the clinic."

ADC Programs

Researchers reported preclinical data at AACR describing how changes in the structure of the attached drugs can affect ADC efficacy and tolerability, the impact that linker structure and these modifications can have on ADC activity, and the ability of Seattle Genetics' ADC technology to effectively deliver active drugs to target tissue while avoiding non-targeted drug release. (Abstracts #4793, #916 and #4088) Further data from preclinical models of ADCs provide mechanistic insight into how and when drugs are r
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
6. Myriad Genetics Presents Tumor Origin Technology at AACR
7. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
8. Myriad Genetics Presents Azixas Mode of Action at AACR
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:5/17/2013)... , May 17, 2013 Medical devices are ... a biological product. In light of their different mechanisms, ... are much more complicated than drug trails due to ... MD safety instead of evaluating both safety and efficacy ... FDA (which is the same as the SFDA) evaluate ...
(Date:5/17/2013)... SAN DIEGO and CAMBRIDGE, Mass., May 17, 2013 ... announce that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: ... District Court for the District of Massachusetts ... of its officers violated the Securities Exchange Act of ... May 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)...  TechAtlas Group has announced the release of ... for the Chronic Kidney Disease (CKD) market. This ... drugs and devices currently on the market and ... (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... renal denervation , diabetic nephropathy - antifibrotics ...
Breaking Medicine Technology:Statistical Challenges in Medical Device Trail Evaluation 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2
... Eli Lilly and Company,(NYSE: LLY ) ... with the,European Medicines Agency (EMEA) for centralised review ... for the,first-line treatment of advanced non-small cell lung ... more than 85 countries as a,second-line, single agent ...
... insulin glargine, exenatide offered added benefits of, ... with metformin --, AMSTERDAM, Netherlands, Sept. 21 ... Eli Lilly and Company (NYSE: LLY ),today ... insulin glargine on beta-cell function, glycemic control and ...
Cached Medicine Technology:Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 2Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 3Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 4Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 5Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 6Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 7Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 8Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 9Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 10Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 11Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 12One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 2One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 3One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 4One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 5One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 6One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 7
(Date:5/20/2013)... WA (PRWEB) May 20, 2013 6Webs.com ... home alarm system reviews . 6Webs.com recently completed their ... the nation. Reviews are completed annually and the top ... factors which include their monitoring technology, equipment and warranties ... 6Webs.com stated, "When the 6Webs.com team completed the home ...
(Date:5/20/2013)... News) -- Dermatologists are saying that new federally ... make smarter choices when it comes to products ... new labels required by the U.S. Food and ... a sunscreen will protect against skin cancer in ... indicate whether a sunscreen is water-resistant, according to ...
(Date:5/20/2013)... Irving, Texas (PRWEB) May 20, 2013 ... and Phytel, the leader in automated, provider-led population ... health systems to effect change and successfully pursue ... of advisory services and technology to accelerate the ... of the VHA IMPERATIVTM performance improvement suite of ...
(Date:5/20/2013)... University in Sweden have mapped the significance of ... studies have previously examined whether different forms of ... coronary heart disease, ischemic stroke, peripheral arterial disease ... siblings and parents have suffered different types of ... is highest for atherosclerosis of the aorta followed ...
(Date:5/20/2013)... 20, 2013 Gilman Law LLP, a ... investigating Byetta lawsuits, is troubled by a new study ... and similar type 2 diabetes drugs are growing. ... Practices (ISMP), found that 71 Byetta pancreatic cancer reports ... Administration (FDA) as of June 30, 2012. ...
Breaking Medicine News(10 mins):Health News:Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com 2Health News:Revised Sunscreen Labels Should Help Consumers Make Wiser Choices 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 2Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 3
... , FRIDAY, Nov. 11 (HealthDay News) -- Vaccination ... type b (Hib) among young children in the United States ... That strain of flu was once the most common cause ... mid-1980s. But the researchers also found that other strains ...
... (November 11, 2011) Children treated at home for severe ... recover than children referred to health facilities, Save the Children ... Lancet medical journal today. The results come the ... world,s attention on the leading cause of child death. ...
... University of Michigan researchers will provide genetic testing and ... mild cognitive impairment. Researchers hope to ... caregivers respond to health education and genetic testing, says ... Behavior and Health Education at the U-M School of ...
... NOVEMBER 10, 2011 Results of the PARTNER ... replacement (TAVR) results in improved quality of life compared ... the transfemoral approach. The results of the study were ... (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. ...
... between the ages of 18 and 25 report the highest ... Survey on Drug Use & Health. A new study from ... in prosocial behaviors, such as volunteering and helping others, are ... Carlo, Millsap Professor of Diversity in the Department of Human ...
... Foundation (AHAF), a nonprofit organization funding innovative research through ... the number of scientists seeking ADR research grants through ... "It,s a sign of difficult times for the ... Guy Eakin, Ph.D. "Finding government funding is tough ...
Cached Medicine News:Health News:Lancet pneumonia study offers new hope for reducing No. 1 cause of child death 2Health News:Lancet pneumonia study offers new hope for reducing No. 1 cause of child death 3Health News:Quality of life benefits of transcatheter aortic valve replacement differ by access site 2Health News:Volunteering, helping others decreases substance use in rural teens, MU study finds 2Health News:Requests for Alzheimer's disease research grants up by 33 percent, as federal funding in doubt 2Health News:Requests for Alzheimer's disease research grants up by 33 percent, as federal funding in doubt 3
Stainless steel flexible ruler. graduated in 1/32 inches (.8 mm) fractions, as well as mm graduations....
Colorado Microneedles offer the surgeon precision in cutting and coagulation, without the expense and inconvenience of a laser. The needles may also be used for dissecting large areas such as the sca...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: